Upcoming Dividend • Jun 25
Upcoming dividend of NT$0.50 per share Eligible shareholders must have bought the stock before 01 July 2026. Payment date: 28 July 2026. Trailing yield: 0.9%. Lower than top quartile of Taiwanese dividend payers (4.9%). Lower than average of industry peers (3.0%). Reported Earnings • Apr 06
Full year 2025 earnings released: EPS: NT$2.62 (vs NT$1.46 loss in FY 2024) Full year 2025 results: EPS: NT$2.62 (up from NT$1.46 loss in FY 2024). Revenue: NT$1.06b (up 53% from FY 2024). Net income: NT$96.3m (up NT$149.9m from FY 2024). Profit margin: 9.1% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year whereas the company’s share price has fallen by 19% per year. 공고 • Mar 11
Prince Pharmaceutical Co., Ltd., Annual General Meeting, Jun 09, 2026 Prince Pharmaceutical Co., Ltd., Annual General Meeting, Jun 09, 2026. Location: no,168, k`o yun s. rd., huwei township, yunlin county Taiwan New Risk • Feb 28
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 36% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (NT$1.07b market cap, or US$34.2m). New Risk • Jun 13
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 16% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$858.4m market cap, or US$29.0m). Reported Earnings • Mar 30
Full year 2024 earnings released: NT$1.46 loss per share (vs NT$0.43 profit in FY 2023) Full year 2024 results: NT$1.46 loss per share (down from NT$0.43 profit in FY 2023). Revenue: NT$690.0m (down 8.4% from FY 2023). Net loss: NT$53.5m (down 450% from profit in FY 2023). 공고 • Mar 13
Prince Pharmaceutical Co., Ltd., Annual General Meeting, Jun 19, 2025 Prince Pharmaceutical Co., Ltd., Annual General Meeting, Jun 19, 2025. Location: no,168, k`o yun s. rd., huwei township, yunlin county Taiwan New Risk • Mar 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (NT$884.0m market cap, or US$26.8m). New Risk • Sep 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Market cap is less than US$100m (NT$841.9m market cap, or US$26.4m). New Risk • Aug 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Profit margins are more than 30% lower than last year (2.0% net profit margin). Market cap is less than US$100m (NT$881.3m market cap, or US$27.0m). Upcoming Dividend • Jun 14
Upcoming dividend of NT$0.25 per share Eligible shareholders must have bought the stock before 21 June 2024. Payment date: 19 July 2024. Payout ratio is a comfortable 27% but the company is paying out more than the cash it is generating. Trailing yield: 0.5%. Lower than top quartile of Taiwanese dividend payers (4.2%). Lower than average of industry peers (2.0%). Reported Earnings • Mar 27
Full year 2023 earnings released: EPS: NT$0.43 (vs NT$1.55 in FY 2022) Full year 2023 results: EPS: NT$0.43 (down from NT$1.55 in FY 2022). Revenue: NT$753.3m (up 5.7% from FY 2022). Net income: NT$15.3m (down 70% from FY 2022). Profit margin: 2.0% (down from 7.2% in FY 2022). The decrease in margin was driven by higher expenses. New Risk • Feb 27
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Profit margins are more than 30% lower than last year (3.4% net profit margin). Market cap is less than US$100m (NT$1.23b market cap, or US$38.8m). Reported Earnings • Aug 13
First half 2023 earnings released: EPS: NT$0.16 (vs NT$1.01 in 1H 2022) First half 2023 results: EPS: NT$0.16 (down from NT$1.01 in 1H 2022). Revenue: NT$356.0m (down 5.5% from 1H 2022). Net income: NT$5.71m (down 83% from 1H 2022). Profit margin: 1.6% (down from 8.9% in 1H 2022). The decrease in margin was primarily driven by lower revenue. New Risk • Aug 11
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 3.4% Last year net profit margin: 6.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (3.4% net profit margin). Market cap is less than US$100m (NT$1.41b market cap, or US$44.3m). Reported Earnings • Apr 23
Full year 2022 earnings released: EPS: NT$1.55 (vs NT$0.25 loss in FY 2021) Full year 2022 results: EPS: NT$1.55 (up from NT$0.25 loss in FY 2021). Revenue: NT$712.5m (up 62% from FY 2021). Net income: NT$51.6m (up NT$59.9m from FY 2021). Profit margin: 7.2% (up from net loss in FY 2021). The move to profitability was driven by higher revenue.